Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24261125 | 0.88 | PTGS2 (0.42) | PTGS2PTGS1SLC6A3SLC6A2BCL2L1 | |
| SCHEMBL19839299 | 0.86 | PTGS2 (0.40) | PTGS2PTGS1SLC6A3SLC6A2BCL2L1 | |
| SCHEMBL19839405 | 0.85 | PTGS1 (0.38) | PTGS2PTGS1NOTUMBCL2L1 | |
| SCHEMBL15538598 | 0.85 | PTGS2 (0.36) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL30857688 | 0.81 | PTGS2 (0.41) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL523660 | 0.80 | PTGS2 (0.44) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL24165531 | 0.76 | SLC6A2 (0.39) | SLC6A2BCL2L1HTR1A | |
| SCHEMBL1742816 | 0.75 | SLC6A3 (0.46) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL1957330 | 0.75 | SLC6A3 (0.46) | PTGS2PTGS1SLC6A3SLC6A2NOTUM | |
| SCHEMBL1957416 | 0.74 | SLC6A3 (0.47) | PTGS2PTGS1SLC6A3SLC6A2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| EP-3494115-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2018027097-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018027097-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | PTGS2 1652/4885PTGS1 2166/4885SLC6A3 4676/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | PTGS2 363/4885PTGS1 562/4885SLC6A3 4688/4885 |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | BCL2A1, BCL3, BCL2 | PTGS2 1334/4885PTGS1 2025/4885SLC6A3 2629/4885 |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | PTGS2 1334/4885PTGS1 2025/4885SLC6A3 2629/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | PTGS2 1334/4885PTGS1 2025/4885SLC6A3 2629/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | PTGS2 178/4885PTGS1 197/4885SLC6A3 3933/4885 |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | PTGS2 1400/4885PTGS1 2063/4885SLC6A3 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.